RSW.L

Renishaw Plc
Renishaw PLC - Trading Statement
24th October 2024, 06:00
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 3723J
Renishaw PLC
24 October 2024
 

Renishaw plc

Trading update

24 October 2024

 

 

Solid revenue and profit growth in mixed trading conditions

Renishaw plc, the global provider of manufacturing technologies, analytical instruments and medical devices, publishes this trading update for the three months ended 30 September 2024. It contains unaudited information that covers the first quarter of the financial year.

 

 

Trading activity

 

 

3 months to 30 September 2024

3 months to 30 September 2023

Change

 

 

 

 

Manufacturing technologies

£167.5m

£156.8m

+7%

Analytical instruments and medical devices

£6.4m

£7.7m

-16%

Total revenue

£173.9m

£164.5m

+6%

Total revenue at constant exchange rates1

£171.3m

£165.0m

+4%


 

 

 

Adjusted profit before tax2

£34.0m

£28.0m

+22%

Statutory profit before tax

£34.0m

£28.0m

+22%

 

 

Revenue was £173.9m, representing a 6% increase compared to the corresponding period last year at actual exchange rates, and a 4% increase at constant currency1. The Americas and EMEA regions saw increased demand compared to Q1 FY2024, whilst APAC was lower compared to a strong period last year, which was boosted by orders from the consumer electronics sector. 

 

In our Manufacturing technologies business, revenue in the period was 7% higher than the prior year at £167.5m.  Sales of position encoders to the semiconductor manufacturing sector saw strong growth compared to a subdued prior year comparator. Our Additive Manufacturing products also grew strongly, reflecting the good order book carried into FY2025.  Meanwhile, demand for Industrial Metrology products was lower than last year, primarily due to the strong prior period sales to consumer electronics manufacturers in APAC.

 

Revenue for our Analytical instruments and medical devices business was £6.4m, a decrease of 16% compared with £7.7m last year, primarily from phasing for our Spectroscopy products.

 

Adjusted and Statutory profit before tax2 for the first quarter of FY2025 both amounted to £34.0m (FY2024: £28.0m).

 

 

Financial position

 

The Group's balance sheet remains strong with net cash and cash equivalents and bank deposit balances of £276.1m on 30 September 2024 (30 June 2024: £217.8m).

 

 

Outlook

 

The first quarter of FY2025 has seen solid revenue and profit growth in mixed trading conditions, with subdued demand in some markets, offset by good growth elsewhere.  Whilst Q1 sales of our encoder products to the semiconductor manufacturing sector have been stronger than last year, we remain cautious about demand from this market in the remainder of FY2025. 

 

We continue to pursue a range of growth opportunities and anticipate solid overall revenue growth this year in line with the Board's expectations.  Alongside this we also remain focused on the careful management of costs and delivery of productivity improvements, which together will help drive progress towards our margin objectives.

The results for the half year ending 31 December 2024 will be released on 13 February 2025.

 

Will Lee

Allen Roberts

 

Chief Executive

Group Finance Director

 



 

24 October 2024


 



 

Renishaw plc


Registered office

New Mills, Wotton-under-Edge, Gloucestershire, GL12 8JR

Registered number

01106260

Telephone number

+44 (0) 1453 524524

Website

www.renishaw.com

 

 

 

Notes

 

1.     Revenue at constant exchange rates is defined as revenue recalculated using the same rates that were applicable to the previous year and excluding forward contract gains and losses.

2.     There are no adjustments made between statutory and adjusted profit before tax.  

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTEAKEDALELFFA]]>
TwitterFacebookLinkedIn